Study S001690

Randomized, Double-blind, Placebo Controlled, Parallel Group, Prospective Clinical Study to Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05303857
Acronym: SEMA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 107
Start: 2022-03-03
Primary completion: 2023-12-15
Lead sponsor: University of Erlangen-Nürnberg Medical School
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide Pen Injector; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Central (aortic) pulse pressure assessed by Sphygmocor XCEL [16 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0049575	EFFECTS OF THE GLP-1 RA SEMAGLUTIDE ON VASCULAR STRUCTURE AND FUNCTION IN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF A PROSPECTIVE RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY Dennis Kannenkeril, Journal of Hypertension	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05303857